title: Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases.
abstract: Many Chinese patients with hematologic diseases, who need allogeneic hematopoietic stem cell transplantation (HSCT), lack a human leukocyte antigen-matched donor. To save these patients and to avoid collecting donor bone marrow graft, we adopted haploidentical peripheral blood HSCT with granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells as the grafts without ex vivo T cell depletion. Thirty-eight patients were enrolled, and they received myeloablative preconditioning. Thirty-five patients attained a successful neutrophil and platelet recovery. The median time for the neutrophil recovery was 16 days (range of 10-23 days), and the median time for the platelet recovery was 19 days (range of 10-66 days). During the follow-up at a median time of 33.1 weeks (range of 1.1-412.6 weeks), eleven (28.9 %) patients developed aGVHD grade I-II and seven (18.4 %) patients developed aGVHD grade III-IV. The incidence of cGVHD was 27.6 %, and nine (23.7 %) patients died within the first 100 days after transplantation. The cumulative survival proportions at 1 and 2 years were 52.51 ± 8.57 % and 43.76 ± 9.11 %, respectively. These results suggested that the G-CSF-primed peripheral blood stem cell grafts, without in vitro T cell depletion, could be an appropriate stem cell source for Haplo-HSCT.
authors.affiliation: Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
authors.forename: Rui-Nan
authors.initials: RN
authors.lastname: Lu
authors.forename: Kou-Rong
authors.initials: KR
authors.lastname: Miao
authors.forename: Run
authors.initials: R
authors.lastname: Zhang
authors.forename: Ming
authors.initials: M
authors.lastname: Hong
authors.forename: Ji
authors.initials: J
authors.lastname: Xu
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhu
authors.forename: Hua-Yuan
authors.initials: HY
authors.lastname: Zhu
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Qu
authors.forename: Shuai
authors.initials: S
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Lei
authors.initials: L
authors.lastname: Fan
authors.forename: Wen-Yi
authors.initials: WY
authors.lastname: Shen
authors.forename: Hua
authors.initials: H
authors.lastname: Lu
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Qiu
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Zhang
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.forename: Jian-Yong
authors.initials: JY
authors.lastname: Li
authors.forename: Han-Xin
authors.initials: HX
authors.lastname: Wu
authors.forename: Si-Xuan
authors.initials: SX
authors.lastname: Qian
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077552:Basiliximab; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006239:Haplotypes; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016019:Survival Analysis; D013601:T-Lymphocytes; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000077552:Basiliximab